JP2014523516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523516A5 JP2014523516A5 JP2014508165A JP2014508165A JP2014523516A5 JP 2014523516 A5 JP2014523516 A5 JP 2014523516A5 JP 2014508165 A JP2014508165 A JP 2014508165A JP 2014508165 A JP2014508165 A JP 2014508165A JP 2014523516 A5 JP2014523516 A5 JP 2014523516A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- pathway
- hsp90
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037361 pathway Effects 0.000 claims description 135
- 206010028980 Neoplasm Diseases 0.000 claims description 130
- 239000003112 inhibitor Substances 0.000 claims description 127
- 201000011510 cancer Diseases 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 112
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 89
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 89
- SUPVGFZUWFMATN-UHFFFAOYSA-N zelavespib Chemical compound N1=CN=C2N(CCCNC(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N SUPVGFZUWFMATN-UHFFFAOYSA-N 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 20
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 13
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 13
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 239000000090 biomarker Substances 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 102100025210 Histone-arginine methyltransferase CARM1 Human genes 0.000 claims description 6
- -1 IKK Proteins 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 239000013060 biological fluid Substances 0.000 claims description 6
- 108010030886 coactivator-associated arginine methyltransferase 1 Proteins 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 4
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 4
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 4
- 101150058731 STAT5A gene Proteins 0.000 claims description 4
- 101150063267 STAT5B gene Proteins 0.000 claims description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 4
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims description 4
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 238000004590 computer program Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 230000010365 information processing Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 238000011260 co-administration Methods 0.000 claims description 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000033077 cellular process Effects 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- IBPVXAOOVUAOKJ-UHFFFAOYSA-N 4-[[2,6-difluoro-4-[3-(1-piperidin-4-ylpyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine Chemical compound FC1=CC(C=2C3=NC(=CN=C3C=CC=2)C2=CN(N=C2)C2CCNCC2)=CC(F)=C1CN1CCOCC1 IBPVXAOOVUAOKJ-UHFFFAOYSA-N 0.000 claims 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 claims 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- JVDOKQYTTYUYDV-UHFFFAOYSA-N TG101209 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C)C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)=N1 JVDOKQYTTYUYDV-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 1
- 229960000215 ruxolitinib Drugs 0.000 claims 1
- 229960004247 tofacitinib citrate Drugs 0.000 claims 1
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 claims 1
- 238000003032 molecular docking Methods 0.000 description 9
- 239000013078 crystal Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- SWDZPNJZKUGIIH-QQTULTPQSA-N (5z)-n-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2h-1,2-oxazole-3-carboxamide Chemical compound O1NC(C(=O)NCC)=C(C=2C=CC(CN3CCOCC3)=CC=2)\C1=C1/C=C(C(C)C)C(O)=CC1=O SWDZPNJZKUGIIH-QQTULTPQSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229950005069 luminespib Drugs 0.000 description 1
- NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480198P | 2011-04-28 | 2011-04-28 | |
| US61/480,198 | 2011-04-28 | ||
| PCT/US2012/035690 WO2012149493A2 (en) | 2011-04-28 | 2012-04-27 | Hsp90 combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016175431A Division JP6375345B2 (ja) | 2011-04-28 | 2016-09-08 | Ｈｓｐ９０併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523516A JP2014523516A (ja) | 2014-09-11 |
| JP2014523516A5 true JP2014523516A5 (enExample) | 2015-06-18 |
| JP6363502B2 JP6363502B2 (ja) | 2018-07-25 |
Family
ID=47073116
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508165A Expired - Fee Related JP6363502B2 (ja) | 2011-04-28 | 2012-04-27 | Ｈｓｐ９０併用療法 |
| JP2016175431A Expired - Fee Related JP6375345B2 (ja) | 2011-04-28 | 2016-09-08 | Ｈｓｐ９０併用療法 |
| JP2018106047A Withdrawn JP2018153194A (ja) | 2011-04-28 | 2018-06-01 | Ｈｓｐ９０併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016175431A Expired - Fee Related JP6375345B2 (ja) | 2011-04-28 | 2016-09-08 | Ｈｓｐ９０併用療法 |
| JP2018106047A Withdrawn JP2018153194A (ja) | 2011-04-28 | 2018-06-01 | Ｈｓｐ９０併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140315929A1 (enExample) |
| EP (1) | EP2701747A4 (enExample) |
| JP (3) | JP6363502B2 (enExample) |
| KR (2) | KR102027448B1 (enExample) |
| CN (2) | CN109498812A (enExample) |
| AU (3) | AU2012249322B2 (enExample) |
| BR (1) | BR112013027448A2 (enExample) |
| CA (1) | CA2833390A1 (enExample) |
| EA (1) | EA201391587A1 (enExample) |
| MX (1) | MX2013012183A (enExample) |
| NZ (1) | NZ618062A (enExample) |
| WO (1) | WO2012149493A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140294725A1 (en) | 2011-07-08 | 2014-10-02 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP3498701B1 (en) | 2012-12-21 | 2023-02-22 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| US10071130B2 (en) | 2013-12-12 | 2018-09-11 | The University Of Chicago | Methods and compositions related to Hsp90 inhibitors and breast cancer |
| EP3086792B1 (en) | 2013-12-23 | 2022-10-12 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| MX2016014365A (es) * | 2014-05-02 | 2017-04-27 | Wistar Inst | Terapias combinadas dirigidas a mitocondrias para la terapia contra cancer. |
| CN107110869B (zh) | 2014-09-17 | 2021-08-10 | 纪念斯隆-凯特琳癌症中心 | Hsp90-靶向炎症和感染成像及治疗 |
| US9754080B2 (en) | 2014-10-21 | 2017-09-05 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions |
| US10073952B2 (en) | 2014-10-21 | 2018-09-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US10325685B2 (en) | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
| US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
| US10777320B2 (en) | 2014-10-21 | 2020-09-15 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions |
| US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| US10381112B2 (en) | 2014-10-21 | 2019-08-13 | uBiome, Inc. | Method and system for characterizing allergy-related conditions associated with microorganisms |
| US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
| US10395777B2 (en) | 2014-10-21 | 2019-08-27 | uBiome, Inc. | Method and system for characterizing microorganism-associated sleep-related conditions |
| US9710606B2 (en) | 2014-10-21 | 2017-07-18 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
| US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
| US10793907B2 (en) | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| US10346592B2 (en) | 2014-10-21 | 2019-07-09 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| EP3209803A4 (en) | 2014-10-21 | 2018-06-13 | Ubiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10311973B2 (en) | 2014-10-21 | 2019-06-04 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US10409955B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions |
| US10366793B2 (en) | 2014-10-21 | 2019-07-30 | uBiome, Inc. | Method and system for characterizing microorganism-related conditions |
| US9760676B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
| US10357157B2 (en) | 2014-10-21 | 2019-07-23 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features |
| US10789334B2 (en) | 2014-10-21 | 2020-09-29 | Psomagen, Inc. | Method and system for microbial pharmacogenomics |
| US10246753B2 (en) | 2015-04-13 | 2019-04-02 | uBiome, Inc. | Method and system for characterizing mouth-associated conditions |
| CN107849616B (zh) * | 2015-04-13 | 2022-03-29 | 普梭梅根公司 | 用于功能特征相关的状况的微生物组来源的表征、诊断和治疗的方法及系统 |
| CN106265660B (zh) * | 2015-05-21 | 2019-08-02 | 中国科学院合肥物质科学研究院 | A674563在携带flt3突变型基因的急性白血病中的用途 |
| CN106349180B (zh) * | 2015-07-14 | 2020-05-19 | 上海翰森生物医药科技有限公司 | 4,5-二苯基异噁唑衍生物及其制备方法和应用 |
| JP7187035B2 (ja) * | 2016-08-03 | 2022-12-12 | アールイーエムディー バイオセラピューティクス，インコーポレイテッド | 癌を治療するためのグルカゴン受容体アンタゴニストとｐｉ３ｋ経路阻害剤との組み合わせ |
| RU2019127350A (ru) * | 2017-02-03 | 2021-03-03 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Способы лечения рака с использованием ингибиторов hsp90 |
| JP2020524156A (ja) | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 標的治療薬を含む併用療法 |
| IL299893A (en) | 2017-06-20 | 2023-03-01 | Madrigal Pharmaceuticals Inc | prescribed medications |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| CN109554343B (zh) * | 2018-12-29 | 2022-04-19 | 吉林大学 | 一种适于神经元粘附与存活的涂层材料及制备方法 |
| CN111467472B (zh) * | 2020-04-21 | 2020-12-25 | 南京中医药大学 | 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用 |
| WO2021252490A2 (en) * | 2020-06-11 | 2021-12-16 | The Children's Medical Center Corporation | Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders |
| CN116615422A (zh) * | 2020-10-14 | 2023-08-18 | 珃诺生物医药科技(杭州)有限公司 | 用于靶向蛋白降解的方法和组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| JP5721949B2 (ja) * | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| EP2491923A3 (en) * | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| WO2008114812A1 (ja) * | 2007-03-19 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | Jak阻害剤 |
| KR20150091434A (ko) * | 2007-07-30 | 2015-08-10 | 아디아 바이오사이언스즈 인크. | 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법 |
| US20100310563A1 (en) * | 2007-11-30 | 2010-12-09 | Bumm Thomas G P | Methods for treating induced cellular proliferative disorders |
| WO2010006072A2 (en) * | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
| US20110319415A1 (en) * | 2008-08-18 | 2011-12-29 | Universit+e,uml a+ee t zu K+e,uml o+ee ln | Susceptibility to HSP90-Inhibitors |
| JP2012510442A (ja) * | 2008-11-28 | 2012-05-10 | ノバルティス アーゲー | Ｈｓｐ９０阻害剤の組合せ |
| US8669289B2 (en) * | 2009-04-24 | 2014-03-11 | The Jackson Laboratory | Methods and compositions relating to hematologic malignancies |
| EP2443123B1 (en) * | 2009-06-15 | 2017-04-05 | Rigel Pharmaceuticals, Inc. | Small molecule inhibitors of spleen tyrosine kinase (syk) |
| ES2608670T3 (es) * | 2009-08-17 | 2017-04-12 | Memorial Sloan-Kettering Cancer Center | Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos |
| EP2499486A4 (en) * | 2009-11-13 | 2013-11-27 | Infinity Pharmaceuticals Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER |
| NZ604040A (en) * | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| EP2714038A1 (en) * | 2011-05-24 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
-
2012
- 2012-04-27 WO PCT/US2012/035690 patent/WO2012149493A2/en not_active Ceased
- 2012-04-27 US US14/113,779 patent/US20140315929A1/en not_active Abandoned
- 2012-04-27 KR KR1020137031561A patent/KR102027448B1/ko not_active Expired - Fee Related
- 2012-04-27 EP EP12777773.8A patent/EP2701747A4/en not_active Withdrawn
- 2012-04-27 MX MX2013012183A patent/MX2013012183A/es unknown
- 2012-04-27 AU AU2012249322A patent/AU2012249322B2/en not_active Ceased
- 2012-04-27 BR BR112013027448-4A patent/BR112013027448A2/pt not_active IP Right Cessation
- 2012-04-27 NZ NZ618062A patent/NZ618062A/en not_active IP Right Cessation
- 2012-04-27 CA CA2833390A patent/CA2833390A1/en not_active Abandoned
- 2012-04-27 CN CN201811083946.3A patent/CN109498812A/zh active Pending
- 2012-04-27 EA EA201391587A patent/EA201391587A1/ru unknown
- 2012-04-27 CN CN201280030064.5A patent/CN103998935B/zh not_active Expired - Fee Related
- 2012-04-27 KR KR1020197028143A patent/KR102196424B1/ko not_active Expired - Fee Related
- 2012-04-27 JP JP2014508165A patent/JP6363502B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-08 JP JP2016175431A patent/JP6375345B2/ja not_active Expired - Fee Related
-
2017
- 2017-12-08 AU AU2017272303A patent/AU2017272303A1/en not_active Abandoned
-
2018
- 2018-06-01 JP JP2018106047A patent/JP2018153194A/ja not_active Withdrawn
-
2020
- 2020-01-14 AU AU2020200262A patent/AU2020200262A1/en not_active Abandoned
- 2020-08-28 US US17/006,359 patent/US20220074941A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523516A5 (enExample) | ||
| Bruix et al. | Insights into the success and failure of systemic therapy for hepatocellular carcinoma | |
| Rizzo et al. | Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review | |
| Remon et al. | The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613 | |
| Fisher et al. | Cancer heterogeneity: implications for targeted therapeutics | |
| Johnson et al. | Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms | |
| Roberts et al. | KRAS mutation: should we test for it, and does it matter? | |
| Nishino et al. | State of the art: response assessment in lung cancer in the era of genomic medicine | |
| Patel et al. | Next-generation sequencing: a novel approach to distinguish multifocal primary lung adenocarcinomas from intrapulmonary metastases | |
| Okines et al. | Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials | |
| Peng et al. | Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA | |
| Dietel | Molecular pathology: a requirement for precision medicine in cancer | |
| Gerger et al. | Molecular predictors of response to antiangiogenesis therapies | |
| Li et al. | Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL | |
| Stahel et al. | Strategies for improving outcomes in NSCLC: a look to the future | |
| Sugihara et al. | A new look at drugs targeting malignant melanoma—an application for mass spectrometry imaging | |
| Watanabe et al. | BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma | |
| Dai et al. | Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection | |
| Grinspan et al. | Biomarker development using liquid biopsy in hepatocellular carcinoma | |
| Zanwar et al. | Extramedullary Myeloma is Genomically Complex and Characterized by Near-Universal MAPK Pathway Alterations. | |
| Shen et al. | Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer | |
| Torricelli et al. | Genomic analysis in short-and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy | |
| Ito et al. | Clinicopathological and molecular characteristics promoting PD-L1 expression in early-stage lung adenocarcinoma and squamous cell carcinoma | |
| Kang et al. | A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17) | |
| Van Cutsem et al. | 803 ORAL analysis of blood plasma factors in the AVITA phase III randomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC) |